ESTRO meets Asia 2024 - Abstract Book

S146

Interdisciplinary – Gynaecological

ESTRO meets Asia 2024

for local control (LC), PFS, and OS were 88.2%, 76.5%, and 88.2% respectively. The 7-year rates for LCR, PFS, and OS were 88.2%, 71.0%, and 81.9% respectively. Multifactorial regression analysis identified pre-treatment hemoglobin levels (<116g/L) as adverse independent prognostic factors affecting PFS ( P<0.05 ), while tumor involvement in the lower 1/3 of the vagina was an adverse independent prognostic factor affecting OS ( P<0.05 ). The most common acute treatment-related adverse reaction was bone marrow suppression, with 23 cases (67.6%) experiencing Grade 3 or higher bone marrow suppression. Only 1 case (2.9%) had a Grade 4 adverse reaction, which was severe thrombocytopenia. Two cases (5.9%) experienced transient palpitations, with no Grade 5 adverse reactions reported.

Conclusion:

The combination of endostar and CCRT can enhance tumor response rates in patients with LACC, prolong PFS and OS, and demonstrate a favorable safety profile. This approach offers a novel treatment choice for individuals with LACC.

Keywords: cervical carcinoma; endostar; CCRT

250

Proffered Paper

evaluation of sexual quality of life in cervical cancer patients undergoing chemoradiotherapy

Subalakshmi Jayapalan, Bhavana Rai, Srinivasa GY, Sandeep Grover, Shalini Gainder, Reena Kumari, Arnav Tiwari, Sushmita Ghoshal

Radiotherapy&oncology, PGIMER, Chandigarh, India

Purpose/Objective:

To evaluate the change in sexual quality of life in cervical cancer patients undergoing chemoradiotherapy and to analyze the clinical and dosimetric factors influencing sexual QOL in these patients.

Material/Methods:

Fifty newly diagnosed locally advanced cervical cancer patients planned for curative treatment were enrolled in this prospective study. Sexual outcomes of patients were measured at the start of treatment, 3,6and9 months post treatment with the structured tools such as CSFQ -14 and EORTC CX24. Baseline sexual QOL of patients were compared to that of 50 healthy controls. The analysis between patient and control groups for continuous outcome was done using Wilcoxon Signed Rank test and Friedmann test. Dosimetric data, patient and disease related factors were analyzed using Mannwhitney test.

Results:

The median age of patients at the time of diagnosis was 52years (range 39-70). Of the 50 patients enrolled three patients had FIGO 2018 stage IB3, 4 stage IIA, 36 IIB, 2 stage IIIA, 3 stage IIIB and 2 stage IIIC. All patients received radical chemoradiation followed by image guided brachytherapy. Forty three (86%) patients received intracavitary whereas 7 patients (14%) received hybrid brachytherapy. The current study indicated that the sexual QOL of cervical cancer patients was comparable to controls at baseline with the exception of decline in interest scores. The survivors had a worse "body image" and increased sexual worry at 6&9 months post treatment compared to